Your account is not claimed yet. You can sign up with ORCID to claim your account.

Pier-Luigi Lollini

ResearcherID Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 19

Top Venues

Cancers

Molecular cancer therapeutics

International journal of molecular sciences

Cells

Universita degli Studi di Bologna

Università degli Studi di Bologna (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Universita degli Studi di Bologna

Italy

Professor

Education History

Università degli Studi di Bologna Nov 1o 1983 - Sep 28o 1987

Italy

PHD

Publications

Maria Cristina Manara, Cristina Manferdini, Camilla Cristalli, Marianna Carrabotta, Spartaco Santi, Alessandra De Feo, Giulia Caldoni, Michela Pasello, Lorena Landuzzi, Pier-Luigi Lollini, Francesca Salamanna, Sabrina Dominici, Valentina Fiori, Mauro Magnani, Gina Lisignoli, Katia Scotlandi
Engagement of CD99 activates distinct programs in Ewing sarcoma and macrophages. Cancer immunology research (2023)
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, Arianna Palladini, Stefania Angelicola, Chiara Cappello, Olga Maria Pittino, Patrizia Nanni, Pier-Luigi Lollini
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy. International journal of molecular sciences 24 (16) (2023)
Lorena Landuzzi, Francesca Ruzzi, Pier-Luigi Lollini, Katia Scotlandi
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research. Cancers 15 (3) (2023)
Lorena Landuzzi, Maria Cristina Manara, Laura Pazzaglia, Pier-Luigi Lollini, Katia Scotlandi
Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma. Cancers 15 (15) (2023)
Lorena Landuzzi, Francesca Ruzzi, Pier-Luigi Lollini, Katia Scotlandi
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research. Cancers 15 (3) (2023)
Francesca Ruzzi, Arianna Palladini, Stine Clemmensen, Anette Strøbæk, Nicolaas Buijs, Tanja Domeyer, Jerzy Dorosz, Vladislav Soroka, Dagmara Grzadziela, Christina Jo Rasmussen, Ida Busch Nielsen, Max Søgaard, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola, Lorena Landuzzi, Pier-Luigi Lollini, Mette Thorn
Prevention and Therapy of Metastatic HER-2 + Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. Biomedicines 10 (10) (2022)
Line Manceau, Julien Richard Albert, Pier-Luigi Lollini, Maxim V C Greenberg, Pascale Gilardi-Hebenstreit, Vanessa C Ribes
Divergent transcriptional and transforming properties of PAX3-FOXO1 and PAX7-FOXO1 paralogs. PLoS genetics 18 (5) (2022)
Marianna Carrabotta, Maria Antonella Laginestra, Giorgio Durante, Caterina Mancarella, Lorena Landuzzi, Alessandro Parra, Francesca Ruzzi, Lisa Toracchio, Alessandra De Feo, Veronica Giusti, Michela Pasello, Alberto Righi, Pier-Luigi Lollini, Emanuela Palmerini, Davide Maria Donati, Maria Cristina Manara, Katia Scotlandi
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4 Sarcoma. Cancer research 82 (4) (2022)
Carla De Giovanni, Lorena Landuzzi, Arianna Palladini, Giordano Nicoletti, Patrizia Nanni, Pier-Luigi Lollini
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy. Cells 10 (7) (2021)
Stefania Angelicola, Francesca Ruzzi, Lorena Landuzzi, Laura Scalambra, Francesco Gelsomino, Andrea Ardizzoni, Patrizia Nanni, Pier-Luigi Lollini, Arianna Palladini
IFN-γ and CD38 in Hyperprogressive Cancer Development. Cancers 13 (2) (2021)
Tommaso Balestra, Maria Cristina Manara, Maria Antonella Laginestra, Michela Pasello, Alessandra De Feo, Cristian Bassi, Clara Guerzoni, Lorena Landuzzi, Pier-Luigi Lollini, Davide Maria Donati, Massimo Negrini, Mauro Magnani, Katia Scotlandi
Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity. Molecular cancer therapeutics (2021)
Veronica Giusti, Francesca Ruzzi, Lorena Landuzzi, Marianna L Ianzano, Roberta Laranga, Elena Nironi, Laura Scalambra, Giordano Nicoletti, Carla De Giovanni, Martina Olivero, Maddalena Arigoni, Raffaele Calogero, Patrizia Nanni, Arianna Palladini, Pier-Luigi Lollini
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression. Oncogenesis 10 (11) (2021)
Lorena Landuzzi, Maria Cristina Manara, Pier-Luigi Lollini, Katia Scotlandi
Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma. Cells 10 (2) (2021)
Matteo Canale, Andrea Casadei-Gardini, Paola Ulivi, María Arechederra, Carmen Berasain, Pier-Luigi Lollini, Maite G Férnandez-Barrena, Matias A Avila
Epigenetic Mechanisms in Gastric Cancer: Potential New Therapeutic Opportunities. International journal of molecular sciences 21 (15) (2020)
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players? Cancers 12 (11) (2020)
Carla De Giovanni, Lorena Landuzzi, Arianna Palladini, Marianna Lucia Ianzano, Giordano Nicoletti, Francesca Ruzzi, Augusto Amici, Stefania Croci, Patrizia Nanni, Pier-Luigi Lollini
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R. Cancers 11 (4) (2019)
Carla De Giovanni, Patrizia Nanni, Lorena Landuzzi, Marianna L Ianzano, Giordano Nicoletti, Stefania Croci, Arianna Palladini, Pier-Luigi Lollini
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. BMC cancer 19 (1) (2019)
Arianna Palladini, Lorena Landuzzi, Pier-Luigi Lollini, Patrizia Nanni
Cancer immunoprevention: from mice to early clinical trials. BMC immunology 19 (1) (2018)
Maria Cristina Manara, Sergio Valente, Camilla Cristalli, Giordano Nicoletti, Lorena Landuzzi, Clemens Zwergel, Roberta Mazzone, Giulia Stazi, Paola B Arimondo, Michela Pasello, Clara Guerzoni, Piero Picci, Patrizia Nanni, Pier-Luigi Lollini, Antonello Mai, Katia Scotlandi
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy. Molecular cancer therapeutics 17 (9) (2018)

Pier-Luigi Lollini.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Pier-Luigi Lollini